drugset / Trial / NCT00706680
Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol
Phase 4
Unknown
30 enrolled
University Health Network, Toronto
Genzyme, a Sanofi Company · collabSt. Paul's Hospital, Canada · collabUnity Health Toronto · collab
NaSingle-groupOpen-labelPrevention
Summary
This study has been designed to test whether using Thymoglobulin with low dose Cyclosporine and early steroid dosage reduction will minimize both kidney rejection and the development of new onset diabetes mellitus after renal transplant.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-02
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymoglobulin | Protein / enzyme biologic | 6 mg/kg | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 7.5 mg/kg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | — |
| Background | Methylprednisone | Unknown | — | Intravenous |
| Background | Prednisone | Other / unclassified | 5 mg | — |
| Background | mycophenolic acid | Small molecule | 1440 mg | — |
| Background | mycophenolic acid | Small molecule | 2 g | — |